Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Deffered Revenue (2016 - 2024)

Seres Therapeutics' Non-Current Deffered Revenue history spans 9 years, with the latest figure at $95.4 million for Q2 2024.

  • For Q2 2024, Non-Current Deffered Revenue changed 0.46% year-over-year to $95.4 million; the TTM value through Jun 2024 reached $95.4 million, changed 0.46%, while the annual FY2023 figure was $95.4 million, 3.17% up from the prior year.
  • Non-Current Deffered Revenue for Q2 2024 was $95.4 million at Seres Therapeutics, roughly flat from $95.4 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $95.4 million in Q4 2023 and bottomed at $2.8 million in Q2 2020.
  • The 5-year median for Non-Current Deffered Revenue is $89.7 million (2021), against an average of $84.5 million.
  • The largest annual shift saw Non-Current Deffered Revenue fell 24.41% in 2020 before it skyrocketed 2675.44% in 2021.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $85.6 million in 2020, then increased by 1.67% to $87.0 million in 2021, then increased by 6.24% to $92.4 million in 2022, then increased by 3.17% to $95.4 million in 2023, then changed by 0.0% to $95.4 million in 2024.
  • Per Business Quant, the three most recent readings for MCRB's Non-Current Deffered Revenue are $95.4 million (Q2 2024), $95.4 million (Q1 2024), and $95.4 million (Q4 2023).